The Trump administration’s handling of leucovorin has become a flashpoint in the debate over autism policy, drug regulation, and public trust. In September 2025, Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary publicly framed leucovorin as a promising option tied to autism-related symptoms. On March 10, 2026, however, the FDA formally expanded the drug’s use only for a rare disorder known as FOLR1-related cerebral folate transport deficiency, not for autism itself. That shift is now raising questions about whether the government oversold the science and then quietly narrowed its position.
What the FDA Actually Approved
Leucovorin, also called folinic acid, is an older drug long used in cancer care and certain folate-related conditions. On September 22, 2025, the FDA said it was taking action to make leucovorin available for people with cerebral folate deficiency, citing a systematic review of literature published from 2009 through 2024. The agency’s announcement said the evidence supported use in individuals suffering from CFD, a condition involving low folate levels in the central nervous system.
The key point is that the March 2026 action did not approve leucovorin as a treatment for autism broadly. According to reporting from STAT, The Washington Post, and Forbes, FDA officials said the evidence was not sufficient to establish efficacy for autism as a whole. Instead, the approval was limited to patients with FOLR1-related cerebral folate transport deficiency, a rare condition that can include developmental delays and autistic features.
That distinction matters medically and politically. Autism spectrum disorder is a broad neurodevelopmental diagnosis, while FOLR1-related cerebral folate transport deficiency is a specific, uncommon disorder. Some patients may overlap, but the FDA’s current position draws a clear regulatory line between treating a rare folate transport problem and treating autism itself.
Bait and Switch? RFK Jr.’s FDA Pivots on ‘Promising’ Autism Treatment Leucovorin
The controversy stems from the contrast between the administration’s earlier rhetoric and the narrower approval that followed. At a White House event on September 22, 2025, Kennedy and Makary presented leucovorin as part of a broader autism initiative. HHS said the FDA would act on a potential treatment for speech-related deficits associated with autism spectrum disorder, and Makary said a growing body of evidence suggested that some children with autism may have brain folate deficiency that could be treated with leucovorin.
By March 10, 2026, the message had changed. FDA officials told reporters that the agency had reviewed whether leucovorin could be used for autism, but did not find enough evidence to support that broader claim. Makary’s later statement described the approval as one that “may benefit some individuals” with FOLR1-related cerebral folate transport deficiency who have developmental delays with autistic features, a much narrower formulation than the administration’s earlier public framing.
Critics argue that this looks like a policy retreat after months of public enthusiasm. Supporters of the administration may counter that the FDA ultimately followed the evidence and confined the label to a condition it believed was supportable. Both interpretations now coexist, but the record shows a real shift in emphasis between September 2025 and March 2026.
The Evidence Behind Leucovorin and Autism
The scientific case for leucovorin in autism has never been straightforward. A number of small studies have explored whether folinic acid may help subsets of autistic children, especially those with language impairment or biomarkers related to folate metabolism. ClinicalTrials.gov lists a randomized study of 134 children ages 5 to 17 examining folinic acid for language impairment in autism spectrum disorder, underscoring that research is ongoing rather than settled.
At the same time, major news and medical coverage has emphasized the limits of the evidence. The Washington Post reported that leucovorin had been tested for autism-related symptoms in only a handful of small trials in the United States and abroad. STAT also reported that the FDA concluded leucovorin lacks sufficient evidence for use as an autism treatment, even after reviewing the literature.
According to Robert Hendren, a retired University of California, San Francisco researcher cited by STAT in October 2025, leucovorin may have “a good place in treatment of ASD,” but he also said he had not seen a remarkable response and that one 12-week trial showed very little change. That kind of mixed assessment reflects the broader state of the field: cautious interest, but no consensus that the drug works for autism broadly.
Why the Pivot Matters for Families and Clinicians
For families seeking treatments, the distinction between a promising therapy and an FDA-approved autism treatment is not academic. Public statements from top health officials can influence prescribing patterns, insurance expectations, and parental decision-making. Forbes reported that a Lancet paper published in early March 2026 found new prescriptions for leucovorin among children ages 5 to 17 rose 71% in the months after the September 2025 White House event.
That increase suggests the administration’s messaging had real-world effects before the FDA clarified the narrower indication. The Washington Post reported that officials noted the drug would still be available for off-label use, meaning physicians may prescribe it outside the approved indication if they judge it appropriate. Off-label prescribing is legal and common in medicine, but it also places greater weight on physician judgment and informed consent when evidence is limited.
For clinicians, the issue is especially sensitive because autism care already sits at the intersection of hope, uncertainty, and intense public scrutiny. Pediatric groups and autism researchers have warned that overstating preliminary findings can confuse families and distort expectations. Fierce Pharma reported in October 2025 that the American Academy of Pediatrics declined to endorse routine use of leucovorin for autism, saying more research was needed.
Regulatory Credibility and the Politics of Autism
The leucovorin episode also speaks to a larger question: how should federal agencies communicate about emerging therapies in politically charged areas? The FDA’s September 2025 announcement relied on a literature review rather than the conventional path of large, modern clinical trials for a new autism indication. That approach drew criticism from some experts who argued the evidence base was too thin for broad public claims.
Kennedy has made autism a central issue in his tenure, including broader federal efforts to study autism data through Medicare and Medicaid systems. The AP reported in May 2025 that HHS planned a data-sharing arrangement between NIH and CMS to study autism and other chronic diseases, a move that itself drew skepticism from experts about whether it could identify root causes.
In that context, the leucovorin pivot is likely to be read as more than a narrow drug-labeling dispute. For critics, it reinforces concerns that autism policy is being shaped by political messaging ahead of scientific consensus. For supporters, it may show that the administration is willing to explore unconventional avenues while still allowing the FDA to stop short of claims it cannot fully support.
What Comes Next
The most likely next phase is not a sweeping reversal, but a prolonged period of narrower clinical use and continued study. Because leucovorin is now approved for a rare folate transport disorder rather than autism broadly, researchers and clinicians will likely focus on identifying which patients, if any, may benefit based on biomarkers or specific metabolic findings. That is a more targeted path than the one implied by the administration’s earlier public rollout.
Further trials will matter. If larger, well-controlled studies show meaningful benefit in defined subgroups of autistic patients, the regulatory picture could change. If they do not, the March 2026 FDA position may stand as the clearest statement yet that leucovorin should not be treated as a general autism therapy.
For now, the central fact is clear: the FDA has not approved leucovorin for autism. It has approved the drug for a rare folate-related disorder that can overlap with autistic features in some patients. That leaves the administration facing a credibility test over whether its earlier messaging got ahead of the evidence.
Conclusion
The dispute over leucovorin is ultimately about more than one drug. It is about how public health agencies describe early evidence, how political leaders frame hope for families, and how regulators maintain trust when science remains unsettled. RFK Jr.’s FDA did move leucovorin forward, but not in the broad way many listeners may have inferred from the administration’s 2025 autism messaging. As of March 11, 2026, the official position is narrower, more cautious, and more clinically specific than the original public pitch.
Frequently Asked Questions
What is leucovorin?
Leucovorin, also known as folinic acid, is an older drug used in several medical settings, including cancer care and folate-related disorders. It is not a new drug developed specifically for autism.
Did the FDA approve leucovorin for autism?
No. As of March 10, 2026, the FDA expanded leucovorin’s use for FOLR1-related cerebral folate transport deficiency, not for autism broadly.
Why are people saying the FDA pivoted?
Because administration officials publicly described leucovorin in 2025 as a promising autism-related treatment, but the FDA later said the evidence was insufficient for an autism indication and approved it only for a rare related disorder.
Can doctors still prescribe leucovorin to autistic patients?
Yes. Physicians may prescribe approved drugs off-label when they believe it is medically appropriate, although that is different from an FDA approval for autism.
Is there evidence that leucovorin helps some autistic children?
There is some early and mixed evidence from small studies, especially in certain subgroups, but the FDA says current data do not support efficacy for autism more broadly.
What should families take from this development?
Families should understand that the FDA’s action is narrower than the earlier public messaging suggested. Decisions about leucovorin should be made with qualified clinicians who can weigh the evidence, possible benefits, and uncertainties for an individual patient.
